- Patent Title: Lactoferrin/albumin fusion protein and production method therefor
-
Application No.: US16344875Application Date: 2017-10-27
-
Publication No.: US11041014B2Publication Date: 2021-06-22
- Inventor: Atsushi Sato , Shinji Kagaya
- Applicant: S & K BIOPHARMA, INC.
- Applicant Address: JP Kawasaki
- Assignee: S & K BIOPHARMA, INC.
- Current Assignee: S & K BIOPHARMA, INC.
- Current Assignee Address: JP Kawasaki
- Agency: Faegre Drinker Biddle & Reath LLP
- Priority: JPJP2016-212077 20161028,JPJP2017-044893 20170309
- International Application: PCT/JP2017/038866 WO 20171027
- International Announcement: WO2018/079702 WO 20180503
- Main IPC: C07K14/79
- IPC: C07K14/79 ; C12N15/62 ; C12N15/82 ; C07K14/765 ; A61P35/00 ; A61K38/40 ; C12N5/10 ; C12P21/02 ; A61P43/00 ; A61P39/04 ; C07K19/00 ; A61K38/38 ; A61P9/10 ; C12N15/09 ; A01K67/027

Abstract:
The present invention provides a lactoferrin fusion protein having high clinical utility and a production method therefor. The present invention further provides: a lactoferrin fusion protein that retains the biological activity of native lactoferrin while having a significantly extended in vivo life span, and that has more clinical utility than native lactoferrin and recombinant lactoferrin; and a production method therefor. With this fusion protein or a variant thereof, the ability of lactoferrin to bind iron is retained, and therefore at least the important biological activity of lactoferrin that is based on the iron-binding ability is retained. Additionally, this fusion protein or variant thereof has bioavailability and resistance to protease, and thus can exhibit biological activity in vivo over a long period. Furthermore, this fusion protein is not easily broken down by pepsin in the stomach.
Public/Granted literature
- US20190309049A1 LACTOFERRIN/ALBUMIN FUSION PROTEIN AND PRODUCTION METHOD THEREFOR Public/Granted day:2019-10-10
Information query